Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$78.99
+1.4%
$87.25
$73.11
$126.89
$5.46B0.111.02 million shs942,075 shs
Neogen Corporation stock logo
NEOG
Neogen
$4.99
-5.5%
$5.58
$3.87
$18.58
$1.08B1.843.25 million shs6.48 million shs
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$28.33
+1.1%
$29.53
$23.77
$49.45
$1.92B0.11.09 million shs1.21 million shs
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$33.97
$33.70
$20.35
$34.38
$1.50B0.23973,737 shsN/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.00%-1.43%+2.81%-19.16%-2.64%
Neogen Corporation stock logo
NEOG
Neogen
0.00%-11.21%-19.52%-43.62%-70.37%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
0.00%-5.19%-12.51%-21.15%-20.44%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.3545 of 5 stars
3.51.00.04.22.32.51.9
Neogen Corporation stock logo
NEOG
Neogen
3.6881 of 5 stars
3.33.00.00.01.83.32.5
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
4.598 of 5 stars
3.24.00.03.82.31.72.5
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$132.6767.95% Upside
Neogen Corporation stock logo
NEOG
Neogen
2.50
Moderate Buy$9.0080.36% Upside
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
2.43
Hold$44.3356.49% Upside
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NEOG, QDEL, VIVO, and LNTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $117.00
5/8/2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$45.00 ➝ $29.00
5/8/2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$44.00
4/22/2025
Neogen Corporation stock logo
NEOG
Neogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.40 ➝ $5.00
4/21/2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$38.00 ➝ $25.00
4/14/2025
Neogen Corporation stock logo
NEOG
Neogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$13.00 ➝ $6.50
4/10/2025
Neogen Corporation stock logo
NEOG
Neogen
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $13.00
3/21/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $122.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B3.56$7.10 per share11.13$15.65 per share5.05
Neogen Corporation stock logo
NEOG
Neogen
$924.22M1.17$1.02 per share4.87$14.52 per share0.34
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$2.78B0.69$35.41 per share0.80$44.38 per share0.64
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$333.02M4.49$1.78 per share19.13$8.41 per share4.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$312.44M$3.5222.4412.52N/A16.55%36.99%20.55%7/30/2025 (Estimated)
Neogen Corporation stock logo
NEOG
Neogen
-$9.42M-$2.23N/A10.18N/A-53.56%2.69%1.82%7/29/2025 (Estimated)
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
-$2.05B-$4.97N/A8.83N/A-12.07%4.71%2.21%7/30/2025 (Estimated)
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$42.46M$0.9735.02N/A12.70%16.74%13.09%N/A

Latest NEOG, QDEL, VIVO, and LNTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
5/7/2025Q1 2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$0.61$0.74+$0.13-$0.19$694.97 million$692.80 million
4/9/2025Q3 2025
Neogen Corporation stock logo
NEOG
Neogen
$0.12$0.10-$0.02-$0.05$225.27 million$221.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Neogen Corporation stock logo
NEOG
Neogen
N/AN/AN/AN/AN/A
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
N/AN/AN/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.49
5.74
5.46
Neogen Corporation stock logo
NEOG
Neogen
0.33
3.91
2.45
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
0.70
1.20
0.66
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.07
3.63
2.46

Institutional Ownership

CompanyInstitutional Ownership
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Neogen Corporation stock logo
NEOG
Neogen
96.73%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
99.00%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
89.72%

Insider Ownership

CompanyInsider Ownership
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
Neogen Corporation stock logo
NEOG
Neogen
1.13%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
0.79%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70069.19 million68.15 millionOptionable
Neogen Corporation stock logo
NEOG
Neogen
2,110217.04 million214.59 millionOptionable
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
6,60067.63 million67.09 millionOptionable
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
70244.01 million43.00 millionOptionable

Recent News About These Companies

Meridian Bioscience Inc (VIVO)
India's smartphone mkt grows 6%, Vivo tops
Precision BioSciences Launches First Hepatitis B Gene-Editing Trial
Meridian Growth Legacy MERDX
Biomerica, Inc. (BMRA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lantheus stock logo

Lantheus NASDAQ:LNTH

$78.99 +1.07 (+1.37%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$79.62 +0.63 (+0.80%)
As of 06/18/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Neogen stock logo

Neogen NASDAQ:NEOG

$4.99 -0.29 (-5.49%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$5.36 +0.37 (+7.31%)
As of 06/18/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

QuidelOrtho stock logo

QuidelOrtho NASDAQ:QDEL

$28.33 +0.30 (+1.07%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$28.33 0.00 (0.00%)
As of 06/18/2025 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Meridian Bioscience stock logo

Meridian Bioscience NASDAQ:VIVO

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.